move up move left move right move bottom

XARELTO® Professional Registration

Register and move to the head of the pack. You will be among the first to receive updated clinical data and information about XARELTO®, as well as invitations to live events, as soon as they become available. You will not receive more than two communications every month from Janssen Pharmaceuticals, Inc.


The information you provide will only be used by Janssen Pharmaceuticals Inc., our affiliates, and our service providers to send you XARELTO® communications and other disease related information. Our Privacy Policy governs the use of the information you provide. By providing the information and selecting the REGISTER button, you indicate you read, understand and agree to these terms.

*Required field.

If you want to stop receiving this information, you may unsubscribe at any time.






Indication and Important saftey Information


  • Reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® (rivaroxaban) and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
  • Treatment of deep vein thrombosis (DVT).
  • Treatment of pulmonary embolism (PE).
  • Reduction in the risk of recurrence of DVT and/or PE in patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at least 6 months.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing knee replacement surgery.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing hip replacement surgery.